Villejuif

• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc … Ended
  2023-503356-27-00 4 2023-09-07 Metastatic colorectal cancer that is resistant to the currently approv
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a therapeutic HPV DC targeting vaccine in patients with Human … Ended
  2022-502930-25-00 7 2023-07-31 reduced risk of relapse of HPV-related oropharyngeal squamous cell car
• A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended
  2023-505627-30-00 7 2023-07-26 Solid Neoplasm
• Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended
  2022-500694-14-00 7 2023-06-02 Head and Neck Squamous Cell Cancer
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects with Metastatic Solid Tumors Ended
  2023-508529-29-00 9 2023-03-08 Metastatic Solid Malignant tumors
• A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patient … Ended
  2023-510021-16-00 1 2023-03-08 Refractory/relapsed (R/R) CD123-positive acute myeloid leukemia (AML)
• Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizu … Ended
  2024-511538-11-00 4 2023-02-07 Non resectable Hepatocellular carcinoma (HCC)
• Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC Ended
  2023-504112-15-00 4 2023-01-04 Metastatic Non-Small Cell Lung Cancer
• SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease Ended
  2024-511713-38-00 4 2022-12-30 Cisplatine induced hearing loss
• Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year … Ended
  2024-512095-35-00 9 2022-12-27 Relapsed or refractory neuroblastoma and other solid tumors (including
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci … Ended
  2022-502078-17-00 4 2022-12-15 unresectable hepatocellular carcinoma
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri
• A First-in-Human Clinical Study with ABBV-CLS-579 alone and in combination in Patients with Advanced Tumor Cancers Ended
  2023-507432-20-00 1 2022-12-10 Metastatic or locally advanced tumors
• Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi … Ended
  2022-500652-37-00 4 2022-12-01 Advanced melanoma refractory to prior checkpoint inhibitor therapy
• A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended
  2023-506369-79-00 4 2022-11-30 Pancreatic ductal adenocarcinoma
• Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors Ended
  2024-512710-17-00 1 2022-11-22 Advanced solid tumors
• Study to see how safe is TNG908 at different doses in patients with solid tumors that have a gene called MTAP missing Ended
  2024-511976-34-00 7 2022-10-31 "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.
• A Phase 2 Study of LTX-315 in Combination with Pembrolizumab in Patients with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy ( … Ended
  2022-500628-31-00 4 2022-10-24 Advanced Melanoma

Showing 817–840 of 961 trials